RSCM
NRIX icon

Rock Springs Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Rock Springs Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-321,050
Closed -$9.29M – 139
2021
Q4 		$9.29M Buy
321,050
+2,600
+0.8% +$78.8K 0.21% 95
2021
Q3 		$9.54M Buy
318,450
+3,100
+1% +$95.7K 0.2% 109
2021
Q2 		$8.37M Buy
315,350
+4,400
+1% +$129K 0.17% 122
2021
Q1 		$9.67M Buy
310,950
+53,700
+21% +$2.03M 0.21% 119
2020
Q4 		$8.46M Sell
257,250
-264
-0.1% -$8.75K 0.18% 119
2020
Q3 		$8.99M Buy
+257,514
New +$6.49M 0.23% 107

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Rock Springs Capital Management's NRIX Position: Q1 2022 in Review

Rock Springs Capital Management sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 321,050 shares — an estimated $9.29M sold.

Rock Springs Capital Management first reported a position in NRIX in Q3 2020 and held it in 6 quarters. The position peaked at $9.67M in Q1 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • Rock Springs Capital Management reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Rock Springs Capital Management sold 321,050 Nurix Therapeutics shares in Q1 2022, an estimated $9.29M.
  • Rock Springs Capital Management first reported a position in Nurix Therapeutics in Q3 2020 and held it in 6 quarters.
  • Rock Springs Capital Management's Nurix Therapeutics position peaked at $9.67M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.